The 3D cell culture market is projected to reach USD 1,846 million by 2024 from USD 892 million in 2019, at a CAGR of 15.7%. The growth in this market is driven by the increasing focus on developing alternatives to animal testing, growing focus on personalized medicine, increasing incidence of chronic diseases, and the availability of funding for research. On the other hand, the lack of infrastructure for 3D cell-based research and the high cost of cell biology research are expected to restrain the growth of this market during the forecast period.
The 3D cell culture market is marked by the presence of several big and small players. Some of the prominent players offering 3D cell culture products include Thermo Fisher Scientific (US), Corning Incorporated (US), Merck KGaA (Germany), Lonza AG (Switzerland), REPROCELL Incorporated (Japan), TissUse (Germany), InSphero (Switzerland) Synthecon (US), 3D Biotek (US), CN Bio (UK), Hamilton Company (US), MIMETAS (Netherlands), Emulate (US), Hµrel Corporation (US), QGel SA (Switzerland), SynVivo (US), Advanced BioMatrix (US), Greiner Bio-One International (Austria), and PromoCell (Germany).
To know about the assumptions considered for the study download the pdf brochure
These players have adopted various growth strategies such as product launches, expansions, acquisitions, partnerships, agreements, and contracts to expand their presence in the 3D cell culture market. Most key players adopted expansions as their primary growth strategy between 2016 and 2019.
Thermo Fisher Scientific dominated the 3D cell culture market in 2018. The company’s leading position can be attributed to its strong brand image and robust product portfolio. The company has a strong foothold in the market with its established brand AlgiMatrix. The company focuses on R&D activities and product launches to further strengthen its position in the market. In 2018, the company invested USD 967 million in R&D activities. It also adopts organic and inorganic growth strategies such as expansions and acquisitions in order to maintain its position in this market. For instance, in October 2018, Thermo Fisher Scientific acquired the Advanced Bioprocessing business of BD (US) to enhance its presence in the cell culture media products market.
Corning offers a number of quality and reliable products in this market. The company has a strong foothold in the market with its established brand Corning Matrigel Matrix. To maintain its leading position in the 3D cell culture market, the company focuses on R&D activities and product launches. The company invested USD 993 million, USD 864 million, and USD 736 million in R&D activities in 2018, 2017, and 2016, respectively.
Merck KGaA has a strong portfolio of 3D cell culture products, such as 3D scaffolds, scaffold-free products, organ-on-a-chip, and bioinks. In order to maintain its strong position in the market, the company focuses on adopting organic as well as inorganic growth strategies such as expansions and strategic alliances. Furthermore, in February 2018, the company invested USD 42 million (EUR 40 million) to build manufacturing and distribution centers in Asia. This investment will support the growing demand for biopharmaceutical manufacturing.
Related Reports:
3D Cell Culture Market by Product (Hydrogel, Hanging Drop, Bioreactor, Microfluidics, Magnetic Levitation), Application (Cancer, Stem Cell, Toxicology, Tissue Engineering), End User (Pharmaceutical, Biotech, Cosmetics), Region - Global Forecast to 2024
Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]